Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product for the treatment of facial lipoatrophy. In addition, the company offers various therapeutic products for the treatment of oncology, and neurological diseases and disorders, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
IPO Year:
Exchange: AMEX
Website: lineagecell.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2024 | $4.00 | Buy | Craig Hallum |
| 11/2/2022 | $5.00 | Outperform | Robert W. Baird |
| 6/14/2022 | $4.00 | Buy | B. Riley Securities |
| 8/19/2021 | $8.00 | Outperform | Noble Capital Markets |
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, May 13, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference call on May 13, 2025, by dialing (800) 7
Fully Virtual Event Scheduled for June 27, 2025 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation, a non-profit organization dedicated to advancing innovative research and improving quality of life for individuals impacted by paralysis, are proud to collaborate and present the 3rd Annual Spinal Cord Injury Investor Symposium ("3rd SCIIS"). This year's event aims to bring together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived experience, patient and community advoc
Lineage Participating in Panel Discussion of Novel Retina Drug Delivery Approaches at Eyecelerator@ Park City 2025 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive Officer, has been invited to join presenters from REGENXBIO Inc., Regenerative Patch Technologies, LLC, Neurotech Pharmaceuticals, Inc., and others, as part of the "I Shall Be Released: Novel Drug Delivery Approaches for Glaucoma and Retina" panel at Eyecelerator@ Park City 2025. The panel will take place on Friday, May 2, 2025 from 12:30pm to 1:30pm M
Positive 24 Month Visual Acuity Data with OpRegen® in Geographic Atrophy Patients Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit Signed Services Agreement with Genentech to Further Support Ongoing OpRegen Development OpRegen Received RMAT Designation from FDA Completed Two Financings Totaling $44 Million in Gross Proceeds; Potential for an Additional $36 Million in Gross Proceeds Upon Full Cash Exercise of Clinical Milestone-linked Warrants Initiated OPC1 Device Delivery Study in Patients with Subacute and Chronic Spinal Cord Injury Hosted Annual Spinal Cord Injury Symposium with Christopher & Dana Reeve Foundation Presented ReSonance™ (ANP1) Preclinical Results
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its fourth quarter and full year 2024 financial and operating results on Monday, March 10, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Monday, March 10, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2024 financial and operating results and to provide a business update. Interested parties may access the conference call on Monday, March 10, 2025, by di
Safety Study of Stem Cell-derived Transplant Includes Subacute and Chronic SCI Patients Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, announced today that the Company has initiated the DOSED (Delivery of Oligodendrocyte Progenitor Cells (OPCs) for Spinal Cord Injury: Evaluation of a Novel Device) clinical study. The DOSED study will evaluate the safety and utility of the Manual Inject Parenchymal Spinal Delivery System (MI PSD System), a novel delivery device developed to deliver OPC1 directly to the area of injury in patients with spinal cord injury (SCI). OP
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that Brian M. Culley, Lineage's Chief Executive Officer, will be presenting at the Oppenheimer 35th Annual Healthcare Lifesciences Conference on February 11, 2025 at 12:40pm ET. The conference is being held virtually February 11-12, 2025. Interested parties can view a replay of the presentation on the Events and Presentations section of Lineage's website. Additional videos are available on the Media page of the Lineage website. About Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics is a
Lineage Has Now Received $30 Million in Gross Proceeds and May Receive an Additional $36 Million in Gross Proceeds Upon the Full Exercise of OpRegen® Clinical Milestone-linked Warrants Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of the second tranche of its previously announced registered direct offering of an aggregate of up to $66 million. The Company had previously received $24 million in gross proceeds at the closing of the first tranche in November 2024. Today, the Company received an additional $6 million in gross proceeds at the closin
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today published a letter to shareholders highlighting the company's recent achievements and outlook for 2025. Dear Fellow Shareholders, We hope you had a restful holiday season and wish you a happy new year. As we look at our plans for the new year, we want to update you on our recent progress and explain why we believe 2025 will be an exciting year for our company. As many of you know, Lineage is an emerging cell therapy company, but we more accurately should be referred to as a cell transplant company. The term cell tran
$30 Million Upfront With Up to an Additional $36 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-linked Common Warrants Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the first closing of its previously announced registered direct offering for the purchase and sale of up to an aggregate of 39,473,688 of Lineage's common shares and accompanying warrants (the "common warrants") to purchase an aggregate of up to 39,473,688 of Lineage's common shares at a combined purchase price of $0.76 per common share and accompanying comm
Craig Hallum initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $4.00
Robert W. Baird initiated coverage of Lineage Cell Therapeutics with a rating of Outperform and set a new price target of $5.00
B. Riley Securities initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $4.00
Noble Capital Markets initiated coverage of Lineage Cell Therapeutics with a rating of Outperform and set a new price target of $8.00
Cantor Fitzgerald initiated coverage of Lineage Cell Therapeutics with a rating of Overweight and set a new price target of $6.00
8-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
DEFA14A - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
DEF 14A - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
10-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
8-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
8-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
DEF 14A - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
PRE 14A - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
424B5 - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
8-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)
Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS"). The 2nd SCIIS aims to accelerate development in SCI research and treatments by bringing together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived exp
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has appointed George A. Samuel III as Lineage's General Counsel and Corporate Secretary. Mr. Samuel will lead the Company's legal operations, bringing extensive corporate, transactional, intellectual property and commercial expertise which spans nearly 15 years across the life sciences and technology sectors as well as in private practice. "We are pleased to welcome George to our leadership team and look forward to his contributions as we build Lineage into a leading cell therapy and cell transplant comp
OpRegen® Clinical Data Continued to Demonstrate Improvements in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) Worldwide License Agreement Secured for a Cancer Immunotherapy Candidate Based on the Lineage VAC Platform Exclusive Agreement Secured to Evaluate a Novel System for Enhanced Delivery of OPC1 Board of Directors Enhanced with Appointments of Healthcare Leaders, Drs. Anula Jayasuriya and Dipti Amin Current Cash and Marketable Securities Expected to Support Operations Well Into 2023 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, tod
Successful Health Care Investment Executive with Extensive Business, Scientific and Medical Knowledge, as well as Broad Industry and Investment Experience Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions, today announced the appointment of Anula Jayasuriya, M.D., Ph.D., M.B.A., to the Company's Board of Directors, effective as of May 4, 2021. Dr. Jayasuriya is a successful healthcare private equity executive and venture capitalist with extensive clinical, industry, entrepreneurial, and investment experience. Dr. Jayasuriya is the Founder & Managing Director of EXXclaim Cap
Medically Trained Senior Executive/Board Member with Extensive Experience in Clinical Research and Drug Development Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions, today announced the appointment of Dr. Dipti Amin, MBBS, FFPM, MRCGP, DCPSA, DCH, DRCOG, DGM, to the Company's Board of Directors, effective as of April 20, 2021. Dr. Amin is an experienced Non-Executive Director and a medically trained senior executive with broad expertise in medicine, pharmacology, healthcare, research, and product development. Dr. Amin has more than 26 years of experience within the pharmac
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, May 13, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference call on May 13, 2025, by dialing (800) 7
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its fourth quarter and full year 2024 financial and operating results on Monday, March 10, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Monday, March 10, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2024 financial and operating results and to provide a business update. Interested parties may access the conference call on Monday, March 10, 2025, by di
OpRegen® Granted Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA ReSonance™ (ANP1) Preclinical Results Presented at 59th Annual Inner Ear Biology Workshop Added to 2024 Russell 3000® Index Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its third quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. "We were delighted to see our partners' continued commitment to the OpRegen program, in this instance by seeking
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, November 14, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its third quarter 2024 financial and operating results and to provide a business update. Interested parties may access the conference call on November 14, 2024, by dialing (800) 715-9871 from the U.S. an
24 Month Visual Acuity Benefits from a Single Administration with OpRegen® Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit Supported OpRegen for Geographic Atrophy in Phase 2a Study in Collaboration with Roche and Genentech Initiated Activities Under Recently Established Services Agreement with Genentech to Support Ongoing Development of OpRegen Program OPC1 Clinical Study Start Up Preparations Ongoing Hosted 2nd Annual Spinal Cord Injury Investor Symposium Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its second quarter 2024 fi
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its second quarter 2024 financial and operating results on Thursday, August 8, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, August 8, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its second quarter 2024 financial and operating results and to provide a business update. Interested parties may access the conference call on August 8th, 2024, by dialing (800) 715-9871 from the U.S. and Ca
Established New Services Agreement with Genentech to Support Ongoing Development of the OpRegen® Program Long-Term Visual Benefits from a Single Administration with OpRegen Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit OpRegen Preclinical Results Presented at 2024 Association for Research in Vision and Ophthalmology Annual Meeting OPC1 Clinical Study Start Up Preparation Underway Received CIRM Grant to Support 2nd Annual SCI Investor Symposium Appointed Charlotte Hubbert, Ph.D., as Vice President of Corporate Development Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therap
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2024 financial and operating results on Thursday, May 9, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2024 financial and operating results and to provide a business update. Interested parties may access the conference call on May 9th, 2024, by dialing (800) 715-9871 from the U.S. and Canada and sh
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2023 financial and operating results on Thursday, March 7, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, March 7, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2023 financial and operating results and to provide a business update. Interested parties may access the conference call on March 7th, 2024, by dialing (800) 715-
Enrollment Continues in Phase 2a Clinical Study of RG6501 (OpRegen®) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Under Management of Genentech, a Member of the Roche Group Additional RG6501 (OpRegen®) Data Presented at 23rd Annual EURETINA Congress and 2023 Eyecelerator Meetings U.S. Patent Issued Covering Manufacturing and Differentiation Process for Retinal Pigment Epithelial (RPE) Cells Company On Track to Submit OPC1 Investigational New Drug Amendment in Q4 2023 Initiated Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership with Eterna Therapeutics Lineage Cell Therapeutic
SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)
SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)
SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)
SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)